Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

China Resources Pharmaceutical Group Ltd. (3320) Stock Price & Analysis

4 Followers

3320 Stock Chart & Stats

HK$4.54-HK$0.08(-1.84%)
At close: 4:00 PM GMT+8
HK$4.25HK$4.5HK$4.75Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
HKD 4.50 - HKD 4.65
52-Week Range
HKD 4.22 - HKD 6.53
Previous Close
HKD 4.63
Volume
N/A
Average Volume (3M)
6.86M
Market Cap
HKD 29.06B
Enterprise Value
HKD 173.67B
Total Cash (Recent Filing)
HKD 44.03B
Total Debt (Recent Filing)
HKD 114.17B
Price to Earnings (P/E)
6.1
Beta
0.54
Next Earnings
N/A
EPS Estimate
N/A
Last Dividend Ex-Date
Sep 10, 2026
Dividend Yield
5.28%

Bulls Say, Bears Say

Bulls Say

Integrated Healthcare Distribution

The integrated distribution model gives the company access to several healthcare customer groups and embeds it across the medicine supply chain. This broad downstream reach can support recurring transaction volume and make the business relevant to hospitals, pharmacies and other providers over multiple quarters.

Steady Revenue Expansion

Steady multi-year revenue expansion indicates that the company is continuing to grow its underlying distribution and healthcare business rather than relying solely on temporary gains. Returning to mid-single-digit growth in 2025 provides a durable base for maintaining operating scale and supporting future cash generation.

Strong Cash Generation

Solid operating and free cash flow provides evidence that reported earnings are being converted into usable funds. Free cash flow has remained high relative to earnings across the period, supporting reinvestment, working-capital needs and dividends while giving the company some financial flexibility.

Bears Say

Thin Net Margins

Very thin net margins leave limited room to absorb cost increases, pricing pressure or operating disruption without affecting bottom-line earnings. Although gross and operating profitability improved modestly, the low net margin means revenue growth may translate into only restrained earnings expansion over the next several quarters.

Rising Leverage

The faster increase in debt than equity raises the company’s financial risk and reduces flexibility in capital allocation. Greater leverage can constrain the ability to fund expansion or withstand weaker operating conditions, while also limiting how much of future cash generation can be directed toward growth.

Limited Debt Coverage

Although cash generation is a relative strength, its small coverage of total debt indicates that deleveraging would likely be slow if credit conditions tightened. This mismatch between recurring cash flow and the debt burden could keep balance-sheet risk elevated and restrict financial flexibility over the medium term.

China Resources Pharmaceutical Group Ltd. News

3320 FAQ

What was China Resources Pharmaceutical Group Ltd.’s price range in the past 12 months?
China Resources Pharmaceutical Group Ltd. lowest stock price was HK$4.22 and its highest was HK$6.53 in the past 12 months.
What is China Resources Pharmaceutical Group Ltd.’s market cap?
China Resources Pharmaceutical Group Ltd.’s market cap is HK$29.06B.
When is China Resources Pharmaceutical Group Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were China Resources Pharmaceutical Group Ltd.’s earnings last quarter?
China Resources Pharmaceutical Group Ltd. released its earnings results on Aug 24, 2026. The company reported HK$0.412 earnings per share for the quarter, missing the consensus estimate of HK$0.47 by -HK$0.059.
Is China Resources Pharmaceutical Group Ltd. overvalued?
According to Wall Street analysts China Resources Pharmaceutical Group Ltd.’s price is currently Undervalued.
Does China Resources Pharmaceutical Group Ltd. pay dividends?
China Resources Pharmaceutical Group Ltd. pays a quarterly dividend of HK$0.101 which represents an annual dividend yield of 5.28%. See more information on China Resources Pharmaceutical Group Ltd. dividends here
What is China Resources Pharmaceutical Group Ltd.’s EPS estimate?
China Resources Pharmaceutical Group Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does China Resources Pharmaceutical Group Ltd. have?
China Resources Pharmaceutical Group Ltd. has 6,282,510,300 shares outstanding.
What happened to China Resources Pharmaceutical Group Ltd.’s price movement after its last earnings report?
China Resources Pharmaceutical Group Ltd. reported an EPS of HK$0.412 in its last earnings report, missing expectations of HK$0.47. Following the earnings report the stock price went down -2.191%.
Which hedge fund is a major shareholder of China Resources Pharmaceutical Group Ltd.?
Currently, no hedge funds are holding shares in HK:3320
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology